Investigation and exploitation of antibody combining sites
Author(s)
Bibliographic Information
Investigation and exploitation of antibody combining sites
(Methodological surveys in biochemistry and analysis / Eric Reid, series editor, 15(B))
Plenum Press, c1985
Available at 7 libraries
  Aomori
  Iwate
  Miyagi
  Akita
  Yamagata
  Fukushima
  Ibaraki
  Tochigi
  Gunma
  Saitama
  Chiba
  Tokyo
  Kanagawa
  Niigata
  Toyama
  Ishikawa
  Fukui
  Yamanashi
  Nagano
  Gifu
  Shizuoka
  Aichi
  Mie
  Shiga
  Kyoto
  Osaka
  Hyogo
  Nara
  Wakayama
  Tottori
  Shimane
  Okayama
  Hiroshima
  Yamaguchi
  Tokushima
  Kagawa
  Ehime
  Kochi
  Fukuoka
  Saga
  Nagasaki
  Kumamoto
  Oita
  Miyazaki
  Kagoshima
  Okinawa
  Korea
  China
  Thailand
  United Kingdom
  Germany
  Switzerland
  France
  Belgium
  Netherlands
  Sweden
  Norway
  United States of America
Note
"Based on the Ninth International Subcellular Methodology Forum entitled Antibody combining sites, held September 3-6, 1984, in Guildford, United Kingdom"--T.p. verso
Includes bibliographies and index
Description and Table of Contents
Table of Contents
#A Antibody Combining Sites, Especially Structure.- #A–1 Antibody combining sites — past, present and future.- #A–2 Variability, modelling and prediction of ?-hairpins with reference to the immunoglobulin fold.- #A–3 Probing the binding sites in crystals of immunoglobulins.- #A–4 Comparative structures of mouse antibody combining sites.- #NC(A) NOTE and COMMENTS related to the foregoing topics*.- #NC(A)–1 An approach to the study of anti-protein antibody combining sites.- #B Production and Characterization of Antibodies, in Contexts such as Receptor Investigation.- #B–1 Investigating the specificity of monoclonal antibodies to protein antigens using ?-galactosidase fusion proteins.- #B–2 Antibody-screening cDNA libraries.- #B–3 Anti-receptor antibodies by the auto-anti-idiotypic route.- #B–4 Production and characterization of anti-morphine anti-idiotypic antibodies.- #B–5 Anti-idiotype antibodies for the study of membrane receptors: the double monoclonal antibody approach.- #NC(B) NOTES and COMMENTS related to the foregoing topics.- #NC(B)–1 Characterization of idiotypes and VH genes of various members of A48-idiotypic network pathway.- #NC(B)–2 Monoclonal internal image anti-idiotypic antibodies of hepatitis B surface antigen.- #NC(B)–3 Structure and expression of genes encoding IgA heavy chains.- #NC(B)–4 Human:mouse antibody-producing transfectoma cell lines.- #NC(B)–5 Different ways to modify monoclonal antibodies.- #NC(B)–6 Restructuring enzymes and antibodies.- #NC(B)–7 Dideoxy mRNA sequencing as a method to analyze antibody diversity.- #NC(B)–8 Effect of multivalent binding on dissociation of monoclonal antibodies from cell surface antigens.- #C Cytoskeletal, Myocyte and Neuronal Studies with Antibodies.- #C–1Immunological approaches and techniques employed in tubulin and microtubule research.- #C–2 Cell-surface events during myogenesis: immunofluorescence analysis using monoclonal antibodies.- #C–3 Differential expression of cell-surface antigens on muscle satellite cells and myoblasts.- #C–4 Cholinergic-specific nerve terminal antigens.- #C–5 Use of antibodies to purify cholinergic nerve terminals.- #NC(C) NOTES and COMMENTS related to the foregoing topics.- #NC(C)–1 An immunological approach to the cell lineage problem in the mammalian CNS.- #NC(C)–2 An enzyme-linked immunosorbent assay for calmodulin.- #NC(C)–3 Intermediate filament diversity as detected by antibodies.- #D Antibody Approaches to Membrane Components Including the T-Cell Receptor.- #D–1 Exploitation of antibodies in the study of cell membranes.- #D–2 Use of polyclonal and monoclonal antibodies in studying complement component C9 as a transmembrane protein.- #D–3 Ca2+-binding proteins located on the cytoplasmic face of the lymphocyte plasma membrane.- #D–4 The T-cell receptor.- #NC(D) NOTES and COMMENTS related to the foregoing topics.- #NC(D)–1 New light on the T-cell receptor in relation to antibody binding sites.- #NC(D)–2 Molecular nature of the T3 antigen of human T lymphocytes.- #NC(D)–3 Organization and expression of the murine T-cell receptor ?-chain gene complex.- #NC(D)–4 Antigen-specific T-cell activation.- #E Antibodies in Relation to Oncology.- #E–1 Requirements by cancer cells for polypeptide growth factors suggest new therapeutic strategies.- #E–2 Monoclonal antibodies to human tumours for targeting cytotoxic drugs.- #E–3 Antigenic modulation as a limiting factor in the treatment of B-cell lymphoma with anti-idiotype antibody.- #E–4 Tumour-associatedcarbohydrate antigens of glycoproteins.- #E–5 Glycolipid antigens: potential in cancer detection and diagnosis.- #NC(E) NOTES and COMMENTS related to the foregoing topics.- #NC(E)–1 Immune surveillance.- #NC(E)–2 WORKSHOP DISCUSSION focused on #E–4, #E–5 & #E–3.- Guidance for ‘uninitiated’ readers.- Corrections to Vol. 13.
by "Nielsen BookData"